Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Systemic therapy in metastatic renal cell carcinoma
J Bedke, T Gauler, V Grünwald, A Hegele… - World journal of …, 2017 - Springer
Purpose Current systemic treatment of targeted therapies, namely the vascular endothelial
growth factor-antibody (VEGF-AB), VEGF receptor tyrosine kinase inhibitor (TKI) and …
growth factor-antibody (VEGF-AB), VEGF receptor tyrosine kinase inhibitor (TKI) and …
Current clinical practice guidelines for the treatment of renal cell carcinoma: a systematic review and critical evaluation
The landscape of local and systemic therapy of renal cell carcinoma (RCC) is rapidly
changing. The increase in the incidental finding of small renal tumors has increased the …
changing. The increase in the incidental finding of small renal tumors has increased the …
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
TK Choueiri, B Escudier, T Powles, NM Tannir… - The lancet …, 2016 - thelancet.com
Background Cabozantinib is an oral inhibitor of tyrosine kinases including MET, VEGFR,
and AXL. The randomised phase 3 METEOR trial compared the efficacy and safety of …
and AXL. The randomised phase 3 METEOR trial compared the efficacy and safety of …
Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN …
Purpose Cabozantinib is an oral potent inhibitor of vascular endothelial growth factor
receptor 2, MET, and AXL and is a standard second-line therapy for metastatic renal cell …
receptor 2, MET, and AXL and is a standard second-line therapy for metastatic renal cell …
CheckMate 025 randomized phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma
B Escudier, P Sharma, DF McDermott, S George… - European urology, 2017 - Elsevier
Abstract Background The randomized, phase 3 CheckMate 025 study of nivolumab (n= 410)
versus everolimus (n= 411) in previously treated adults (75% male; 88% white) with …
versus everolimus (n= 411) in previously treated adults (75% male; 88% white) with …
Updated European Association of Urology Guidelines: recommendations for the treatment of first-line metastatic clear cell renal cancer
T Powles, L Albiges, M Staehler, K Bensalah… - European urology, 2018 - Elsevier
The randomised phase III clinical trial Checkmate-214 showed a survival superiority for the
combination of ipilimumab and nivolumab when compared with the previous standard of …
combination of ipilimumab and nivolumab when compared with the previous standard of …
Estrogen receptor β promotes renal cell carcinoma progression via regulating LncRNA HOTAIR-miR-138/200c/204/217 associated CeRNA network
Recent studies indicated that the estrogen receptor beta (ERβ) could affect the progression
of prostate and bladder tumors, however, its roles in the renal cell carcinoma (RCC), remain …
of prostate and bladder tumors, however, its roles in the renal cell carcinoma (RCC), remain …
circCHST15 is a novel prognostic biomarker that promotes clear cell renal cell carcinoma cell proliferation and metastasis through the miR-125a-5p/EIF4EBP1 axis
CP Gui, B Liao, CG Luo, YH Chen, L Tan, YM Tang… - Molecular cancer, 2021 - Springer
Abstract Background Circular RNAs (circRNAs) have been indicated as potentially critical
mediators in various types of tumor progression, generally acting as microRNA (miRNA) …
mediators in various types of tumor progression, generally acting as microRNA (miRNA) …
Sunitinib: ten years of successful clinical use and study in advanced renal cell carcinoma
RJ Motzer, B Escudier, A Gannon, RA Figlin - The oncologist, 2017 - academic.oup.com
The oral multikinase inhibitor sunitinib malate was approved by the US Food and Drug
Administration in January 2006 for use in patients with advanced renal cell carcinoma …
Administration in January 2006 for use in patients with advanced renal cell carcinoma …
Commensal microbiota contributes to predicting the response to immune checkpoint inhibitors in non‐small‐cell lung cancer patients
C Zhang, J Wang, Z Sun, Y Cao, Z Mu, X Ji - Cancer Science, 2021 - Wiley Online Library
Immunotherapy against cancer, through immune checkpoint inhibitors targeting the
programmed cell death‐1/programmed cell death‐ligand 1 axis, is particularly successful in …
programmed cell death‐1/programmed cell death‐ligand 1 axis, is particularly successful in …